http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-061899-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052
filingDate 2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f44b3df060e436d532a1580cb8c909e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f64bf0cc2417e795572fa15c2e83c33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3ecff1a6f9a0d206a8874e0f8f585ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abf1957d4ea576a3f4b7335ad3b4738e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_552024d2b7763e18550a2250ff521761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a87c9dfaa6f48500988c1d325c041d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a26f06b74cb5753a82233b391220eb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c6090ded0e26fe96207cc555af70550
publicationDate 2008-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-061899-A1
titleOfInvention BENZIMIDAZOLILO COMPOUNDS AND PHARMACEUTICAL COMPOSITION
abstract Compounds and pharmaceutically acceptable salts of the compounds are described. Pharmaceutical, antiansiolytic compositions are also described for the treatment of neuronal injury, sclerosis, Alzheimer's, anxiety, muscle spasm. Claim 1: A compound of formula 1 or a pharmaceutically acceptable salt thereof, wherein: X3 = CR6; X2 = CR8; X8 = CR3; R1, R2, R3, R4 and R6 are each independently selected from the group consisting of: hydrogen, halogen, - CN, -OR101, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkylaryl, heteroaryl, -C (O) R101, - C (O) OR101, -C (O) NR101R102, -NR101R102 and -NR101S (O) 2R103, in which each of R1, R2, R3, R4 and R6 alkyl, alkenyl cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl , is optionally independently substituted with one or more substituents independently selected from the group consisting of: halogen, cyano, -R101, -OR101, -NR101R102, -S (O) qR103, -S (O) 2NR101R102, -NR101S (O) 2R103, OC (O) R103, -C (O) OR103, -C (O) NR101R102, -NR101C (O) R103 and C (O) R103; or two substituents attached to adjacent carbon atoms of the ring containing X2, X3 and X8, together with adjacent carbon atoms, form a heterocyclic or carbocyclic ring that is optionally substituted with one or more R10, in which each R10 is selected regardless of the group consisting of: hydrogen, -CN, halogen, -C (O) R101, -C (O) NR101R102, -NR101R102, -OR101 or -R101; q is 0, 1 or 2; each R101 and each R102 is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl or R101 and R102 together with the N atom to which they are attached, form a heterocycloalkyl or heteroaryl ring ; wherein each R101 and each R102 alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl is optionally independently substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl optionally substituted with one or more halogen or alkoxy or aryloxy, aryl optionally substituted with one or more halogen or alkoxy or alkyl or trihaloalkyl, heterocycloalkyl optionally substituted with aryl or heteroaryl u = O or alkyl optionally substituted with hydroxy, optionally substituted cycloalkyl with hydroxy, heteroaryl optionally substituted with one or more halogen or alkoxy or alkyl or trihaloalkyl, haloalkyl, hydroxyalkyl, carboxy alkoxy, aryloxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl; R103 is independently selected from the group consisting of: alkyl, alkenyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl and is optionally substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl optionally substituted with one or more halogen or alkoxy or aryloxy, aryl optionally substituted with one or more halogen or alkoxy or alkyl or trihaloalkyl, heterocycloalkyl optionally substituted with aryl or heteroaryl u = O or alkyl optionally substituted with hydroxy, optionally substituted cycloalkyl with hydroxy, heteroaryl optionally substituted with one or more halogen or alkoxy or alkyl or trihaloalkyl, haloalkyl, hydroxyalkyl, carboxy, alkoxy, aryloxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl; X1 = CR7; b = 0, 1 or 2; b1 = 1 or 2; each of R5, R8 and R9 is independently selected from the group consisting of: halogen, cyano, -R401, -OR401, -C (O) OR401 and -NR401R402; R7 is: hydrogen, halogen, hydroxyl, alkyl, alkoxy, cyano or alkyl-CO- or R5 and R7 taken together form a second bond; R18 is hydrogen, halogen or alkyl; R19 is hydrogen or -R8 and -R19 form together = O; wherein R401 and R402 are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl; wherein each of the substituents R401 and R402 alkyl, alkenyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl is optionally independently substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, - R411, -C (O) R413, -C (O) OR413, -C (O) NR411R412, -OR411; -OC (O) R413, -NR411R412; -NR411C (O) R413, -NR411C (O) OR413, -NR411S (O) 2R413, -S (O) tR413, -S (O) 2NR411R412; t is 0, 1 or 2; R411 and R412 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl; R413 is independently selected from the group consisting of: alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl; wherein the substituents R411, R412 and R413 alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl are each optionally independently substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, alkyl, aryl, heterocycloalkyl, heteroaryl, haloalkyl, hydroxyalkyl, carboxy, alkoxy and alkoxycarbonyl or R4 and R5 together with the atoms that bind R4 and R5; they form a 5-7 membered carbocyclic or heterocyclic ring that optionally contains a heteroatom selected from O, N and S or if b = 1 and b1 = 1, R5 and R9 together with the atoms that join R5 and R9 form a carbocyclic ring or 5-7 membered heterocyclic containing up to two heteroatoms selected from O, N and S, in which the carbocyclic or heterocyclic ring is optionally substituted with one or more substituents selected from: halogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or C (O) R20, wherein R20 is alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl and R20 is optionally substituted with one or more substituents independently selected from the group consisting of: alkyl, alkoxy, aryloxy, cyano, -CO2 -alkyl and -OC (O) alkyl or R4 and R7 together with the atoms joining R4 and R7 form a 5-7 membered carbocyclic or heterocyclic ring, in which if the ring formed by R4 and R7 together with the atoms that joins n R4 and R7 is a heterocyclic ring, the heterocyclic ring formed by R4 and R7 together with the atoms that join R4 and R7 contains a heteroatom selected from the group of O, N and S or R5 and R7 together with the atoms that join R5 and R7 forms a 3-7 membered carbocyclic or heterocyclic ring, in which if the ring formed by R5 and R7 together with the atoms that join R5 and R7 is a heterocyclic ring, the heterocyclic ring formed by R5 and R7 together with the atoms that join R5 and R7 contains a heteroatom selected from the group of O, N and S or R1 and R4 together with the atoms that join R1 and R4 form a 5-7 membered carbocyclic or heterocyclic ring in which if the ring formed by R1 and R4 together with the atoms that join R1 and R4 is a heterocyclic ring, the heterocyclic ring formed by R1 and R4 together with the atoms that join R1 and R4 contains a heteroatom selected from the group of O, N and S in which the ring carbocyclic or heterocyclic formed by R4 and R7 together with the atoms that join R4 and R7, by R5 and R7 together with the atoms that join R5 and R7 or by R1 and R4 together with the atoms that join R1 and R4, are optionally substituted with one or more substituents independently selected from: halogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl and -C (O) R20, wherein R20 is: alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl and R20 is optionally substituted with one or more alkyl, alkoxy, aryloxy, cyano , -CO2-alkyl or -OC (O) alkyl; R17 is selected from the group consisting of: alkyl, alkenyl, cycloalkyl and cycloalkenyl, wherein R17 alkyl, alkenyl, cycloalkyl or cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano , nitro, -R501, OR501, - NR501R502, -S (O) vR503, -S (O) 2NR501R502, -NR501S (O) 2R503, -OC (O) R503, -C (O) OR503, -C (O ) NR501R502, -NR501C (O) R503 and -C (O) R503; v is 0, 1 or 2; wherein each R501 and each R502 is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl and heteroaryl; R11, R12, R13 and R14 are each independently selected from the group consisting of: halogen, cyano, -R601, -C (O) OR601, -C (O) NR601R602, -OR601, - OC (O) R602, - NR601R602 and -NR601C (O) R602 in which R601 and R602 are each independently selected from the group consisting of: hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl; wherein the substituents R601 and R602 alkyl, alkenyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl are each optionally independently substituted with one or more substituents independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, -R611, - C (O) R613, -C (O) OR613, -C (O) NR611R612, -OR611, -OC (O) R613, -NR611R612, -NR611C (O) R613, -NR611C (O) OR613, -NR611S ( O) 2R613, -S (O) uR613, -S (O) 2NR611R612; u is 0, 1 or 2; R611 and R612 are each independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl; R613 is independently selected from the group consisting of: alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl or R11 and R17 together with the atoms that join R11 and R17 form a 5-8 membered ring containing 1-2 heteroatoms selected from N, O or S, in which the 5-8 membered ring, formed by R11 and R17 together with the atoms joining R11 and R17 is optionally substituted with one or more substituents independently selected from: halogen, cyano, nitro, -R621, -C (O) R623 -OR621-NR621R622: -NR621C (O) R623; R621 and R62
priorityDate 2006-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396411
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458427722

Total number of triples: 42.